CORTICOSTEROID REDUCTION IN ASTHMA AND THE BRAIN (CRAB) PILOT PROJECT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 轻度至中度持续性哮喘患者将接受开放标签顺序减少吸入皮质类固醇剂量，从每天两次的220微克丙酸氟替卡松减少到不吸入类固醇，目的是降低他们的哮喘控制水平。将在这项为期10周的研究中进行一系列神经成像研究(FMRI)，并将在哮喘控制措施(包括症状、生理反应和呼吸道炎症的措施)的背景下检查大脑反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Mild to moderate persistent asthmatics will undergo an open-label sequential reduction of inhaled corticosteroid dosing, from 220 mcg twice daily of fluticasone propionate to no inhaled steroids, with the goal of reducing their level of asthma control. Serial neuroimaging studies (fMRI) will be obtained over this 10-week study and brain responses will be examined in the context of measures of asthma control (including measures of symptoms, physiologic responses, and airway inflammation).